Eli Lilly (LLY) Research & Development (2009 - 2026)

Eli Lilly has reported Research & Development for 18 years, with the latest figure at $3.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 28.38% year-over-year to $3.5 billion; the trailing twelve-month figure through Mar 2026 stood at $14.1 billion (up 25.99% YoY), and the FY2025 full-year result was $13.3 billion, up 21.34% from the prior year.
• Research & Development for Q1 2026 stood at $3.5 billion, down from $3.8 billion in the prior quarter.
• The five-year high for Research & Development was $3.8 billion in Q4 2025, with the low at $1.6 billion in Q1 2022.
• Historically, Research & Development has averaged $2.6 billion across 5 years, with a median of $2.6 billion in 2023.
• Annual changes were most pronounced in 2022 — Research & Development dropped 3.71% — and 2023, when it jumped 33.62%.
• Eli Lilly's Research & Development stood at $2.0 billion in 2022, then climbed by 28.38% to $2.6 billion in 2023, then grew by 17.98% to $3.0 billion in 2024, then advanced by 25.76% to $3.8 billion in 2025, then slipped by 7.67% to $3.5 billion in 2026.
• The last three Research & Development figures came in at $3.5 billion (Q1 2026), $3.8 billion (Q4 2025), and $3.5 billion (Q3 2025), per Business Quant data.